Association of elevated vitamin B with oncohematological diseases in a cohort of 79,524 patients from Latvia.

Aim: Currently there are some large-scale studies of elevated total vitamin B in relation to diseases and their prognosis. Aim of this retrospective study was to determine association of increased B as an additional diagnostic marker of oncohematological diseases by a statistical analysis of clinical data of 79,524 patients.

Materials And Methods: Overall Latvian population representative data on B  testing in 79,524 patients were obtained from laboratory database. The following exclusion criteria were applied: fluctuating B results within a three-month period, elevated (> 100 U/L) alanine transaminase or aspartate transaminase, hepatitis (HAV, HBV, and HCV) infection, reduced glomerular filtration rate (< 45 mL/min/1.73 m2). As a control group, individuals with normal B level and any oncologic diagnosis (solid cancer or hematological malignancies) were selected.

Results: After application of step-by-step exclusion filters, 1,373 patients were left with significantly increased level of plasma B (> 1,700 pg/mL). Odds ratios for oncohematological diseases in total and myeloid leukemia (including acute, chronic and unspecified) in patient group with elevated B were found to be 6.0 (95% CI 4.7-7.6; p < 0.0001) and 19.2 (95% CI 13.1-28.0; p <0.0001), respectively, as compared to the control group.

Conclusion: Elevated total B could be considered as a potential marker for oncohematological disorders.